Merck & Co.

Merck reports positive results for Keytruda combination in malignant pleural mesothelioma

Merck &Co (Merck) – known as MSD outside the US and Canada – has reported positive results from a phase 2/3 study of its anti-PD-1 therapy Keytruda (pembrolizumab) in combination ... The safety profile of the combination was also consistent with

Sanofi to acquire Provention Bio in deal worth $2.9bn

Through the acquisition, Sanofi will gain access to recently-approved type 1 diabetes prevention therapy Tzield (teplizumab-mzwv), for which the companies already have a co-promotion agreement. ... Ashleigh Palmer, chief executive officer and co-founder

BioNTech and Weizmann Institute to collaborate at company’s new mRNA centre in Israel

Professor Ugur Sahin, chief executive officer and co-founder of BioNTech, said: “We are pleased to establish mRNA research laboratories on the campus of the Weizmann Institute of Science.

Eli Lilly signs agreement worth up to $600m for Confo Therapeutics' non-opioid pain candidate

Confo has retained a co-investment option, which would allow the company to participate in the funding of future development programmes after clinical proof-of-concept for additional royalties.

Moderna/Merck’s skin cancer therapy given FDA breakthrough therapy designation

Moderna and Merck – known as MSD outside the US and Canada – have said their investigational personalised mRNA cancer vaccine, in combination with Merck’s Keytruda, has been given breakthrough therapy designation ... Dr Eric Rubin, senior vice

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]